Archives
-
Phosphatase Inhibitor Cocktail 3: Evidence in Context
2026-10-03
Phosphatase Inhibitor Cocktail 3 can support protein phosphorylation preservation when dynamic signaling pathways are evaluated after sample collection. This article connects its analytical role to the RNF166–angiomotin–YAP mechanism reported in colorectal cancer while distinguishing preservation of phosphoproteins from proof of pathway causality.
-
BAPTA Calcium Chelator for Apoptosis Research
2026-10-02
BAPTA provides a practical way to test whether altered Ca2+ handling is causal in toxin-induced cell death rather than merely correlated with it. This guide translates nanoplastic–cadmium findings into reproducible calcium signaling workflows, control strategies, and troubleshooting decisions for cell-based research.
-
KIR2.1 Inhibition in Pulmonary Vascular Remodeling
2026-10-01
The reference study links KIR2.1 activity with pulmonary artery smooth muscle cell proliferation, migration, and vascular remodeling through the TGF-β1/SMAD2/3 pathway. By combining a monocrotaline-induced rat model with human cell experiments using ML133 and SB431542, it provides a pharmacological framework for studying Kir2.1 potassium channel function in pulmonary hypertension.
-
v-Agatoxin-IVA and Low-Affinity N-Type Ca Blockade
2026-10-01
Sidach and Mintz showed that v-Agatoxin-IVA is not uniformly selective across neuronal calcium-channel populations: it potently blocks P-type channels but also produces weaker, voltage-dependent inhibition of N-type and related high-threshold currents at micromolar exposure. The study demonstrates why toxin concentration, gating behavior, and neuronal preparation must be considered when assigning P-, Q-, or N-type identities.
-
Spinal EAATs and Connexin 43 in Breakthrough Cancer Pain
2026-09-30
This study introduces a recurrent endothelin-1 mouse model for breakthrough cancer pain and identifies coordinated changes in spinal astrocytic EAATs and connexin 43 signaling. Its pharmacological experiments suggest that enhancing EAAT2 or blocking connexin 43-related communication can reduce pain hypersensitivity, providing a framework for mechanistic and translational research.
-
HBTU Workflow for Bioluminescent Peptide Probes
2026-09-30
HBTU combines rapid carboxylic acid activation with a mild, racemization-resistant route to peptide bond formation. This workflow connects practical peptide synthesis with the preparation of enzyme-responsive probes for immunoproteasome activity assays, while separating established chemistry from forward-looking assay applications.
-
2-APB: From Ca2+ Signal to Causal Proof
2026-09-29
Explore how 2-APB (2-aminoethoxydiphenyl borate) can convert calcium imaging into mechanistic evidence. This guide emphasizes temporal assay design, pathway-specific controls, and interpretation of ER calcium signaling in cell-fate and injury models.
-
PS Nanoplastics and Cadmium Drive Intestinal Apoptosis
2026-09-29
A 2026 Toxicology study shows that polystyrene nanoplastics and cadmium jointly promote intestinal apoptosis in C. elegans and Caco-2 cells through the IP3R/Ca2+/STAT3 axis. Inhibitor and calcium-chelation experiments provide functional evidence that intracellular calcium dysregulation links co-exposure to endoplasmic reticulum stress and cell death.
-
ML133 HCl: Interpreting Kir2.1 Assays
2026-09-28
ML133 HCl is a selective potassium channel inhibitor for dissecting Kir2.1-dependent signaling in vascular cell models. This guide goes beyond compound description by showing how pH, assay design, pathway controls, and orthogonal readouts shape interpretation in pulmonary hypertension research.
-
Natural-Product Screening Identifies SARS-CoV-2 NSP15 Leads
2026-09-28
A structure-based screen of natural products identified thymopentin and oleuropein as leading predicted binders of SARS-CoV-2 NSP15, an endoribonuclease linked to viral evasion of innate immunity. Molecular-dynamics simulations supported the stability of the modeled complexes, but biochemical and infection-model validation is needed before either compound can be considered an antiviral inhibitor.
-
KR-12: From Membrane Mechanism to Translation
2026-09-27
KR-12 is a minimal LL-37-derived peptide with focused antimicrobial activity and additional reported biofilm, LPS, and host-response effects. This evidence-led perspective separates established findings from translational hypotheses and offers a framework for building more informative KR-12 studies.
-
Ertugliflozin Workflows for SGLT2 Research
2026-09-26
Use Ertugliflozin (PF-04971729) to probe renal glucose transport and verify SGLT2 target engagement, with practical guidance for formulation, dosing, and glucosuria readouts. A comparative mouse heart-injury study also shows why matched glucose-excretion effects should not be mistaken for equivalent cardioprotection.
-
UBR1 and UBR2: Mammalian ER Stress Sensors
2026-09-25
The study identifies the N-recognin E3 ligases UBR1 and UBR2 as stress-responsive components of mammalian protein quality control: they are normally turned over through Lys48-linked ubiquitination and the 26S proteasome, but become more stable during ER stress. Loss of both proteins increases sensitivity to ER-stress-induced apoptosis, connecting the N-degron pathway to ER homeostasis while leaving the precise sensing mechanism unresolved.
-
BAPTA Calcium Chelator for Apoptosis Workflows
2026-09-25
Use BAPTA to test whether calcium availability contributes to apoptosis—not as a pathway-specific inhibitor. A nanoplastic–cadmium intestinal-cell study offers a practical benchmark for combining calcium chelation with exposure controls and pathway readouts.
-
v-Agatoxin-IVA Blocks Neuronal N-Type Ca Channels
2026-09-24
Sidach and Mintz showed that v-agatoxin-IVA blocks neuronal calcium currents with different potencies: it strongly inhibits P-type current but, at micromolar exposure, also affects a smaller, mixed population that includes N-type channels. Their recordings caution against identifying channel subtypes from toxin sensitivity alone and clarify how concentration and voltage conditions shape pharmacological selectivity.